{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-034951","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.839914+00:00","generated_at":"2026-05-15T08:50:50.716682+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Quoin raises up to $104.5M, advances QRX003 regulatory path, reports 2025 net loss $15.8M","bullets":["Closed private placement for up to $104.5M ($16.5M at closing, $88M warrant potential).","FDA grants Fast Track Designation; single Phase 3 study may suffice for NDA; plan to file in 2027.","Orphan Drug Designations for QRX003 in Netherton Syndrome in US and Europe; Rare Pediatric Disease Designation could yield $150-200M PRV.","Pediatric Netherton study expanded to 7 children with sustained skin healing, no adverse events; Peeling Skin study to 6 subjects.","Cash $18.7M at Dec 31, 2025; net loss Q4 $4.3M vs $2.3M YoY; full year $15.8M vs $9.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-034951","json":"https://secwatch.observer/filing/0001104659-26-034951.json","markdown":"https://secwatch.observer/filing/0001104659-26-034951.md","text":"https://secwatch.observer/filing/0001104659-26-034951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926034951/0001104659-26-034951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926034951/tm269662d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:50:50.716682+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc1d00f6b3f1bf342b22c525729d94a49620efb6","claim":"Quoin Pharmaceuticals, Ltd. reported financial results for fourth quarter and fiscal year 2025.","evidence_excerpt":"Quoin Pharmaceuticals Ltd. (the \"Company\") announced its fourth quarter and fiscal year 2025 financial results. A copy of the Company's press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926034951/0001104659-26-034951-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}